Evaluation of Efficacy of QR678 and QR678 Neo Hair Growth Factor Formulation in the Treatment of Persistent ChemotherapyI Induced Alopecia Caused Due to Cytotoxic Chemotherapy A Prospective Pilot Stud

Abstract

Background: Cancers are one of the main reasons of morbidity and mortality glob-
ally. Chemotherapy-induced alopecia (CIA) is one of the most alarming, terrifying, and
traumatic adverse effects. A range of therapeutic measures has been suggested to
alleviate CIA, but at present, there is no accepted pharmacological therapy that can
assure prevention or management.

Aim: The aim of the present study was to evaluate the efficacy of QR 678 Neo®
therapy in the treatment of persistent chemotherapy-induced alopecia in women and
men treated with cytotoxic chemotherapy for breast and lung cancers, respectively.

Methods: A total of 8 male patients with history of lung cancer and 12 female pa-
tients with history of breast cancer in the age range of 25-60 years, with WHO clas-
sification of grade I and II persistent alopecia who had undergone chemotherapy
treatment, were selected for the study. At each visit, 1.5 mL solution of QR 678® was
injected into the scalp skin of patients. A total of 8 sessions were performed at an
interval of 3 weeks each. All the patients were evaluated with standard global pho-
tography, video microscopic assessment, and patient self-assessment questionnaire
at baseline, 6 months, and 1 year.

Results: Marked improvement was seen in the global assessment score at 6 months
(mean-8) which was maintained even after 1 year. Mean score increase in hair count
at 6 months was 12.71 which further increased at 1 year. High satisfaction score was
given by patients for slowing of hair loss (mean = 4.2) and also for overall hair growth.
For appearance and growth of hair, the mean value was 3.4 and 3.8, respectively.

Conclusion: The formulation of QR 678® and QR 678® Neo showed to be signifi-
cantly safe and efficient for chemotherapy-induced alopecia in both men and women.
Improvement in hair growth was maintained even at 1 year of follow-up. No patient
had any severe adverse effects, and injections were also easily bearable by most of
them.

For full article open PDF